Anemia and the use of antihypertensive medications in hemodialysis patients: multicenter retrospective observational study
Open Access
- 4 February 2019
- journal article
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 1(61),p. 29-38
- https://doi.org/10.31450/ukrjnd.1(61).2019.04
Abstract
We hypothesized that the use of antihypertensive medications in patients treated by hemodialysis (HD) may interfere with the activity of erythropoietin and leads to an increase in the dose of erythropoiesis stimulating agents (ESAs). The aim of our study was to analyze the impact of antihypertensive medications on the effectiveness of anemia treatment. Methods. We conducted a multicenter retrospective observational study. The archival medical data from 379 patients treated by HD or hemodiafiltration (HDF) were used. The medical records of 142 patients were excluded from the study. The study group consisted of 237 patients: 108 (45.6%) women and 129 (54.4%) men, with an average age of 54 [41-62.5] years. Results. The analysis of the mean hemoglobin (Hb) stratified by the administration of antihypertensive medications in the dynamics of dialysis treatment demonstrated a significant impact of angiotensin-converting enzyme (ACE) inhibitors (F = 3.97; p = 0.048) and amlodipine (F = 6.9; p = 0.01) on the effectiveness of anemia correction. The significant effect of amlodipine on the need to increase the dosage of iron-containing medications (OR = 3.9; 95% CI (1.27-12.06), p = 0.002; RR = 1.9 95% CI (1.27-2.9) and continuous erythropoietin receptor activator (CERA) (OR = 5.2, 95% CI (1.2-24.4), p = 0.03; RR = 1.3 95% CI (1, 08-1.6), p = 0.006) weas showed by logistic regression analysis. The increased risk of failure to achieve of the target Hb level in HD patients received amlodipine was confirmed by Cox regression model (HR = 2.7 (95% CI 1.5-4.7)). Conclusions: The results of our study demonstrated a significant increase in the frequency of appointment and amount of anti-anemia therapy in HD patients when amlodipine is co-administered. Follow-up studies to determine the effect of amlodipine mechanism for anemia will avoid unreasonable prescriptions for the treatment of НD patients. Conflict of interest statement: the authors declared no competing interests.Keywords
This publication has 21 references indexed in Scilit:
- History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in NephrologyAmerican Journal of Nephrology, 2017
- Erythropoiesis-Stimulating Agent Hyporesponsiveness in End-Stage Renal Disease PatientsExpanded Hemodialysis: Innovative Clinical Approach in Dialysis, 2015
- Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysisQJM: An International Journal of Medicine, 2015
- AcknowledgmentsKidney International Supplements, 2012
- Effects of the Renin-Angiotensin System Blockade on Hemoglobin Levels in Type 2 Diabetic Patients With Chronic Kidney DiseaseAmerican Journal of Hypertension, 2008
- Antihypertensive Medications and AnemiaThe Journal of Clinical Hypertension, 2007
- Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)Nephrology, 2007
- Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunctionJournal of Invasive Cardiology, 2005
- Appendix D: Methodology of the revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal FailureNephrology Dialysis Transplantation, 2004
- Worsening of Anemia Induced by Long-Term Use of Captopril in Hemodialysis PatientsAmerican Journal of Nephrology, 1984